Nimesh Gupta
 | The topic of this article may not meet Wikitia's general notability guideline. |
Nimesh Gupta | |
|---|---|
| Born | December 05, 1980 |
| Known for | Virology
Immunology Vaccinology |
| Scientific career | |
| Institutions | Institute Pasteur, Paris, France
Centre de Recherche des Cordeliers, Paris, France National Institute of Immunology, Delhi, India |
| Website | https://www.nimeshlab.com/ |
Dr. Nimesh Gupta is a leading vaccine immunologist. He is a senior scientist and leading Vaccine Immunology Laboratory at the National Institute of Immunology, India. Nimesh has made seminal contributions in the field of T-cell immunity to vaccines. Nimesh studies the T-cell determinants of long-term and broadly protective immunity, in context of virus infection and vaccination. Nimesh has found Human immune monitoring and T-cell assay platform for vaccine evaluation.
Education and Academic Posts
Dr. Nimesh completed Bachelor of Science in Microbiology and Masters of Science in Biotechnology from Jiwaji University, Gwalior. He then completed his Ph.D. in 2011 from Jiwaji University and DRDO, Gwalior.
Nimesh went to Institute Pasteur, Paris, France in 2008 as a Raman Charpak Fellow for his doctoral studies. He then continued his postdoctoral research from 2011 in the team of Sebastian Lacroix Desmazes at Centre de recherche des Cordeliers, Paris studying T-cell Immunology and immunity to viruses. He later joined the National Institute of Immunology, [1] India in 2015 as a Scientist and established the Vaccine Immunology Laboratory.
Research
Nimesh's research has focused on T cell immunity to virus infection and vaccines. Research programs in his lab are based on the longitudinal cohorts of controlled vaccination and human virus infections like Dengue, Japanese encephalitis and COVID-19. In collaboration with AIIMS, Nimesh published the first report from India on the immune response to COVID-19 causing virus "SARS-CoV-2" revealing that Indian population already have cross-reactive T cells to SARS-CoV-2 prior to the pandemic, and that the immune memory response (T cells and B cells) to SARS-CoV-2 has durability traits [2] [3]. The study was helpful to mark the kind of immunity generated in the Indian population following the exposure to SARS-CoV-2. In 2021, Nimesh joined the subgroup of the Vaccine Expert Committee, Department of Biotechnology to study the immunology of COVID-19 vaccines and infection in India. In multi-centric collaboration, Nimesh published the first comprehensive report globally on the traits of immune memory response to any inactivated virus vaccine. The study provided first evidence on the quality and durability of immune memory established by the inactivated virus Covid-19 vaccine and its response to SARS-CoV-2 variants[4][5]. This research helped in understanding how COVID-19 vaccine works and provided evidence for scheduling booster immunisations. To help the vaccine industries, Nimesh now leads an advanced Human Immune Monitoring and T-cell Assay Platform that is highly instrumental in testing vaccines in Phase 3 clinical trials, immuno-bridging trials[6] etc.
Nimesh's team also provided crucial knowledge on the mechanism of protective immunity induced by the historical live attenuated Japanese encephalitis (JE) vaccine (SA14142)[7]. In close collaboration with Shane Crotty and Alessandro Sette, Nimesh's team has found vital information on the quality and durability of protective immunity induced by SA14142 JE vaccine. The findings will have direct implications for the policymaking in vaccine implementation.
As a vaccine immunologist, Nimesh has substantially contributed in spreading the public awareness about vaccines and immunology through several public and academic platforms.
Public Outreach
- Arogya Bharat - DD News
- Gyan Vigyan - Rajya Sabha
- Science Monitor - Rajya Sabha
- India fights back - RSTV
- Science Monitor - Vigyan Prasar, DST
- Perspective - Sansad TV
Awards and Honors
- Young Scientist award for the contribution in COVID-19 immunology research in India in the International Science festival-2020 organised by the Ministry of Science and technology, Ministry of Earth Sciences, Ministry of Health and Family Welfare, Govt. of India in collaboration with Vijnana Bharti (VIBHA) (2021)
- ADVAC Fellowship for Advance vaccinology course certification by University of Geneva, Switzerland and The Merieux foundation, France (2019)
- The Martin Villar Award for the best pre-clinical research globally by Grifols and World Federation of Hemophilia (2016)
- Ramalingaswami Fellowship of Department of Biotechnology, Govt. of India (2016)
- Young investigator award by International society on thrombosis and haemostasis, Netherlands (2013)
References
- ↑ "Home | NII". nii.res.in. Retrieved 2023-05-18.
- ↑ "Common cold cross immunity has been protecting Indians in low fatality rate worldwide". The Times of India. 2020-12-01. ISSN 0971-8257. Retrieved 2023-05-18.
- ↑ Ansari, Asgar; Arya, Rakesh; Sachan, Shilpa; Jha, Someshwar Nath; Kalia, Anurag; Lall, Anupam; Sette, Alessandro; Grifoni, Alba; Weiskopf, Daniela; Coshic, Poonam; Sharma, Ashok; Gupta, Nimesh (2021). "Immune Memory in Mild COVID-19 Patients and Unexposed Donors Reveals Persistent T Cell Responses After SARS-CoV-2 Infection". Frontiers in Immunology. 12: 636768. doi:10.3389/fimmu.2021.636768. ISSN 1664-3224. PMC 7991090. PMID 33777028.
- ↑ "Covaxin can help in controlling the virus load of SARS-CoV-2 & its variants, reducing disease severity: Study". pib.gov.in. Retrieved 2023-05-18.
- ↑ Vikkurthi, Rajesh; Ansari, Asgar; Pai, Anupama R.; Jha, Someshwar Nath; Sachan, Shilpa; Pandit, Suvechchha; Nikam, Bhushan; Kalia, Anurag; Jit, Bimal Prasad; Parray, Hilal Ahmad; Singh, Savita; Kshetrapal, Pallavi; Wadhwa, Nitya; Shrivastava, Tripti; Coshic, Poonam. "Inactivated whole-virion vaccine BBV152/Covaxin elicits robust cellular immune memory to SARS-CoV-2 and variants of concern". Nature Microbiology. 7 (7): 974–985. doi:10.1038/s41564-022-01161-5. ISSN 2058-5276.
- ↑ "World's first intra-nasal vaccine for COVID developed by India has got approval from the Central Drugs Standard Control Organisation (CDSCO) for restricted use in emergency situations in the age group of 18 and above". pib.gov.in. Retrieved 2023-05-18.
- ↑ Kalia, Anurag; Agrawal, Mona; Gupta, Nimesh. "CD8+ T cells are crucial for humoral immunity establishment by SA14-14-2 live attenuated Japanese encephalitis vaccine in mice". European Journal of Immunology. 51 (2): 368–379. doi:10.1002/eji.202048745. ISSN 1521-4141. PMID 32749679.
External links
This article "Nimesh Gupta" is from Wikipedia. The list of its authors can be seen in its historical. Articles taken from Draft Namespace on Wikipedia could be accessed on Wikipedia's Draft Namespace.